Efsun Er Somay’s Post

🌟Daily Dose of Motivation for Aspiring Oncology Clinical Pharmacist 🌟 Embarking on the journey to become an Oncology Clinical Pharmacist is no small feat-it takes dedication, resilience,and a thirst for continuous learning.📚💪 👉Just like a sugar pill 💊 that combats hypoglycemia, consider daily motivation as your booster to overcome fears and unlock the vast potential within you 💊✨ Reminders 🌿 Daily learning is the key 🗝️ 🌱Face Your Fears 🌸Enjoy your Progress 🌟Stay Inspired 👉 Remember that your journey is unique, and the challenges you face today will shape the skilled and compassionate Oncology Pharmacist you'll become tommarow 🌿 #Dailymotivation #Oncology #ClinicalPharmacist #ContinuosLearning #DreamBig

𝗜𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳 𝗼𝗳 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿 𝘁𝗵𝗲𝗿𝗲 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗾𝘂𝗶𝘁𝗲 𝘀𝗼𝗺𝗲 𝗮𝗰𝘁𝗶𝗼𝗻 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆. 📈 🧬Therapeutic focused areas of most active buyers: 💰 Novartis closed 4 deals across the following: Oncology and Autoimmune/Inflammatory 💰Johnson & Johnson Innovative Medicine closed 3 deals across Oncology and Inflammatory Diseases 💰Merck Group have also closed 3 deals. Two of them being in oncology and one in ophthalmology 💰AstraZeneca following up the pattern with 2 deals. One being in Oncology and the other in Endocrine Disease 💰AbbVie also close 2 deals in Autoimmune/Inflammatory 🔎𝗪𝗵𝗮𝘁 𝘄𝗶𝗹𝗹 𝘄𝗲 𝘀𝗲𝗲 𝗶𝗻 𝗛𝟮 𝗼𝗳 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿? : There is a clear focus on oncology and autoimmune diseases which should remain key areas, with high premiums for promising early-phase assets... Let me know your thoughts in the comments below ⬇️ #Biotech #BioPharma #BioNews #MasonHarding

When the complexities of designing and executing cancer trials in a highly competitive market can mean delays in delivering urgently needed treatments to patients, it pays to have a trusted partner by your side. 📽️Watch our video to learn how we can support your oncology or hematology therapy needs > https://hubs.li/Q02J9lfN0 #VeristatYouTube #oncology #hematology

"Pharmacist-led Therapeutic Drug Monitoring" I'm excited to share our recent publication in Personalized Medicine on #pharmacistled Therapeutic Drug Monitoring (TDM), focusing on optimizing #vancomycin dosing in pediatric #oncology. Our research highlights the pharmacist's crucial role in ensuring safe and effective #medicationuse, with a 91.7% #adherence to initial TDM #recommendations with #pharmacistintervention. "Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management." Why does this matter? TDM is key to #personalizingmedication for each child, ensuring the right dose at the right time. This is especially crucial in pediatric oncology, where patients often have complex medical needs. Pharmacist-led TDM can significantly enhance #patientsafety and improve treatment outcomes by minimizing the risks of #adversedrugreactions and antibiotic resistance. I'm deeply grateful to my co-authors and the entire team at the Children's Cancer Hospital Egypt 57357 for their dedication to this important work. Read the full paper here: https://lnkd.in/d28PGfvR What are your thoughts about the #pharmacistrole in TDM? Mohamed Ali Hussein Sherif Kamal#pediatrics #oncology #pharmacists #TDM #personalizedmedicine #research #PersonalisedMedicationManagement #precisionmedicine #pharmacy

Becoming an Oncology Clinical Pharmacist 📢 In case you have missed out the session.Its here. ❓Have more questions feel free to ask in the comment box below.

This white paper examines the characteristics of leadership styles and multidisciplinary teams in the context of oncology clinical care. I invite you to join our Oncology TEAM as an experienced CRA Field Monitor. We are hiring.

Flowcytometry applications in oncology

Enhancing the Data Journey in Oncology Clinical Trials

New report out now: Hematologic Cancer Opportunities for Patient Equality (HOPE): Geographic Disparities in Access, Reimbursement, and Hematology Therapy Utilization. Hematological cancer incidence is projected to increase by 55% by 2050, from 1.3 million in 2022 to 2.03 million in 2050. Yet trends in hematological malignancy access aren’t as well understood as oncology patient access. This report showcases: ✅ Trends regarding the availability of therapies for hematological malignancies across selected countries. ✅ Trends in overall regulatory approvals, health technology assessments, reimbursement, and final therapy usage have been analyzed for drugs. ✅ A comparison of these trends with similar ones for solid tumors. ✅ Important dynamics associated with hematology, such as the prevalence of combination therapies and approval based on Phase I/II or III data. ✅ Potential drivers of these trends and the challenges faced by hematology drugs. ✅ The implications of these findings and provides a call to action for policies. Download the report here: https://bit.ly/3xoV81c #Hematology #HealthEquity #GlobalHealth #IQVIAMIDAS

The stakes are high at #JPM24: 5 #FDA decisions to watch in Q1'24 (which will no doubt shape the year). adding about #imaging to each of this trials * Eli Lilly and Company's donanemab for #Alzheimer's disease: This drug could be a competitor to Eisai US and Biogen's Leqembi, and if approved, it would be the first Alzheimer's drug to use #MRI / #PET imaging to track its progress. *Madrigal Pharmaceuticals' resmetirom for MASH: This drug could be the first to market for the metabolic dysfunction-associated #steatohepatitis, a condition previously called #NASH. MASH detection and patient response use #MRI or #CT imaging to assess liver fat content. *Merck.'s sotatercept for pulmonary arterial hypertension: This drug could offer a new direction in treating PAH, and it uses #MRI or #CT imaging to assess #lung function. Iovance Biotherapeutics, Inc. Biotherapeutics' lifileucel for #melanoma: This personalized cell therapy could be the first industrialized TIL therapy, and it uses #MRI or #CT imaging to track tumor response. Of here, an opportunity to deeply look at biologic nature of tumor response with more advanced #imaging and #endpoints. Regeneron Pharmaceuticals' odronextamab for #lymphoma: This bispecific antibody could be a new treatment option for lymphoma, and it uses MRI or CT imaging to assess tumor response, in combination with PET and patient analytics. Interested to learn more, meet our team at #JPM24! Reach out to imaging.experts@ia-grp.com after #neurology #drugdevelopment #liverhealth #clinicaltrial #respiratorymedicine #cardiovascular #oncology #immunotherapy #hematology #biotechinnovation #FDAdecisions #Q12024 #healthcare #pharma